4.7 Article

Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates

期刊

GASTROINTESTINAL ENDOSCOPY
卷 71, 期 6, 页码 976-982

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.gie.2009.11.051

关键词

-

资金

  1. GI Dynamics, Inc

向作者/读者索取更多资源

Background: The duodenojejunal bypass liner (DJBL) (Endo Barrier Gastrointestinal Liner) is an endoscopically placed and removable intestinal liner that creates a duodenojejunal bypass resulting in weight loss and improvement in type 2 diabetes mellitus. Objective: Weight loss before bariatric surgery to decrease perioperative complications. Design: Prospective, randomized, sham-controlled trial. Setting: Multicenter, tertiary care, teaching hospitals. Patients: Twenty-one obese subjects in the DJBL arm and 26 obese subjects in the sham arm composed the intent-to-treat population. Interventions: The subjects in the sham arm underwent an EGD and mock implantation. Both groups received identical nutritional counseling. Main Outcome Measurements: The primary endpoint was the difference in the percentage of excess weight loss (EWL) at week 12 between the 2 groups. Secondary endpoints were the percentage of subjects achieving 10% EWL, total weight change, and device safety. Results: Thirteen DJBL arm subjects and 24 sham arm subjects completed the 12-week study. EWL was 11.9% +/- 1.4% and 2.7% +/- 2.0% for the DJBL and sham arms, respectively (P < .05). In the DJBL arm, 62% achieved 10% or more EWL compared with 17% of the subjects in the sham arm (P < .05). Total weight change in the DJBL arm was -8.2 +/- 1.3 kg compared with -2.1 +/- 1.1 kg in the sham arm (P < .05). Eight DJBL subjects terminated early because of GI bleeding (n = 3), abdominal pain (n = 2), nausea and vomiting (n = 2), and an unrelated preexisting illness (n = 1). None had further clinical symptoms after DJBL explantation. Limitations: Study personnel were not blinded. There was a lack of data on caloric intake. Conclusions: The WE achieved endoscopic duodenal exclusion and promoted significant weight loss beyond a minimal sham effect in candidates for bariatric surgery. (Clinical trial registration number: NPT00469391.) (Gastrointest Endosc 2010;71:976-82.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据